N-methoxymethyl-5,5-diphenylbarbituric acid
AssigneeTaro Pharmaceuticals Industries, Ltd.
InventorsDaniela Gutman, Hershel Herzog
Life of this patent
Estimating the term…
Loading patent…
AssigneeTaro Pharmaceuticals Industries, Ltd.
InventorsDaniela Gutman, Hershel Herzog
Estimating the term…
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I: with an alkylating agent of structure III: in the presence of a basic catalyst in aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbrbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.
A method for making N-methoxymethyl-5,5-diphenylbarbituric acid comprising reacting a ureide of structure I:
A method according to claim 26, further comprising separating the N-methoxymethyl-5,5-diphenylbarbituric acid.
A pharmaceutically acceptable salt of N-methoxymethyl-5,5,-diphenylbarbituric acid.
A method of treating a mammal in need of treatment for a medical condition selected from convulsions, seizures, muscle stiffness, nervous strain, and anxiety, comprising administering an effective amount of a pharmaceutically-acceptable salt of N-methoxymethyl-5,5-diphenylbarbaturic acid in a pharmaceutically-acceptable carrier to the mammal.
Dependencies are inferred from the claim text.